Biopharmaceutical Analysis

Synthace has raised $35 million in funding to fuel growth of its life sciences R&D technology.

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

The partnership between Waters and Sartorius aims to accelerate speed and increase accuracy in bioprocessing analysis.

Gentronix has expanded it lab facilities and increased capacity for genetic, ocular, and skin toxicology testing.

Thermo Fisher Scientific showcases its new mass spectrometry and chromatography solutions at the ASMS Conference on Oct. 31–Nov. 4, 2021.

Automatic visual inspection machines and artificial intelligence highlight inspection deficits for parenteral containers and units.

The need for improved analytics grows.

MilliporeSigma’s newly launched Millicell DCI Digital Cell Imager quickly and objectively assesses common cell culture parameters and growth trends for more consistent cell cultures.

SGS’s new Antwerp, Belgium, clinical research site will house both clinical trial patients and good manufacturing practice drug manufacturing, and its Glasgow, UK, biosafety testing site now has increased testing capacity.

SGS is investing in a new E&L lab in Navi Mumbai, India, that will provide testing services.

AION Labs will be a first-of-its-kind AI/pharma and computational biology innovation lab aimed at spearheading the adoption of AI technologies and computational science.

The expansion to SGS’s Poitiers facility in France is expected to improve the company’s drug development capabilities.

Establishing a data management strategy in-lab is a first step in generating successful analytical studies.

Establishing bioassay studies for biosimilar development is important for supporting regulatory filings.

In September, Codex DNA released a full-length synthetic genome for the SARS-CoV-2 delta variant, which may accelerate discovery and development of diagnostics and treatments for COVID-19.

The new LabVantage Enterprise SaaS adds full configurability and custom interfacing capabilities.

Gyros’ new titer kit identifies adeno-associated virus serotype 9 in vector-based cell and gene therapy manufacturing.

USP is publishing the analytics-focused chapter, which considers validation activities, in advance of the official publication.

CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.

Vector Laboratories has completed a $124 million cash buyout backed by Thompson Street Capital Partners and will begin an acquisition strategy to expand protein detection capabilities.

The US government has granted Thermo Fisher Scientific a $192.5 million contract that the company will use to expand domestic manufacturing for pipette tips.

Element’s acquisition of Impact Analytical expands their life sciences footprint in North America.

Establishing analytical workflows for complex biopharmaceutical molecules can help predict their risk of degradation.

Scientific advances open the way to alternatives to animal testing and in-vivo assays.

The University of Southern California and Amgen have teamed up to provide researchers access to two of Thermo Fisher Scientific’s cryo-EM instruments.

A new membrane staining kit, ExoBrite, launched by Biotium aims to enhance the detection of exosomes through flow cytometry.

Eli Lilly and Company and industry partners, including Ziath, are focused on speeding up the drug discovery process with a fully automated lab.

BioMed X has partnered with Janssen to start two new research programs for autoimmune diseases and drug delivery.

Promega will demonstrate applications of bioluminescence tools at Discover Glo 2021.